The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 1 June 2004 doi:10.1084/jem.20040719
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 199, Number 11, 1451-1454
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 75K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tarlinton, D. M.
Right arrow Articles by Hodgkin, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tarlinton, D. M.
Right arrow Articles by Hodgkin, P. D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Autoimmune Diseases
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Commentary

 Targeting Plasma Cells in Autoimmune Diseases

David M. Tarlinton and Philip D. Hodgkin

The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia

Address correspondence to David M. Tarlinton, Immunology Div., The Walter and Eliza Hall Institute, 1G Royal Parade, Parkville, Victoria 3050, Australia. Phone: 61-3-9345-2615; Fax: 61-3-9347-0852; email: tarlinton{at}wehi.edu.au


Abstract
Antibodies specific for self-antigens mediate life-threatening pathology in several autoimmune diseases. Clearly the ability to target the plasma cells (PCs) producing the autoantibodies would be of great clinical benefit. Current immunosuppressive therapies are based on the premise that autoreactive PCs are short-lived and replenished from ongoing immune responses. However, recent results question this assumption and suggest that optimizing the treatment of severe autoimmune conditions will require a significant investment in elucidating the details of PC biology.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS